Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Oct;49(10):e315-e375.
doi: 10.1111/1346-8138.16527. Epub 2022 Aug 22.

English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021

Hidehisa Saeki  1 , Yukihiro Ohya  2 , Junichi Furuta  3 , Hirokazu Arakawa  4 , Susumu Ichiyama  1 , Toshio Katsunuma  5 , Norito Katoh  6 , Akio Tanaka  7 , Yuichiro Tsunemi  8 , Takeshi Nakahara  9 , Mizuho Nagao  10 , Masami Narita  11 , Michihiro Hide  7   12 , Takao Fujisawa  10 , Masaki Futamura  13 , Koji Masuda  6 , Tomoyo Matsubara  14 , Hiroyuki Murota  15 , Kiwako Yamamoto-Hanada  2
Affiliations
Practice Guideline

English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021

Hidehisa Saeki et al. J Dermatol. 2022 Oct.

Abstract

This is the English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, descriptions of three new drugs, namely, dupilumab, delgocitinib, and baricitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords: atopic dermatitis; clinical practice guidelines; clinical questions; evidence-based medicine; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Kawashima M, Takigawa M, Nakagawa H, Furue M, Iijima M, Iizuka H, et al. Guidelines for management of atopic dermatitis. Jpn J Dermatol. 2000;110:1099-104.
    1. Furue M, Furukawa F, Hide M, Takehara K, Japanese Dermatological Association. Guidelines for therapy for atopic dermatitis 2003. Jpn J Dermatol. 2003;113:451-7.
    1. Furue M, Furukawa F, Hide M, Takehara K. Japanese Dermatological Association Guidelines for therapy of atopic dermatitis 2004. Jpn J Dermatol. 2004;114:135-42.
    1. Furue M, Saeki H, Furukawa F, Hide M, Ohtsuki M, Nakamura T, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2008;118:325-42.
    1. Furue M, Saeki H, Furukawa F, Ohtsuki M, Katayama I, Sasaki R, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2009;119:1515-34.

Publication types

MeSH terms

LinkOut - more resources